CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced the supporting of a CME course discussing AR-V7 in prostate cancer and a poster presentation of the design and rationale for ARMOR3-SV, the planned pivotal Phase 3 trial of galeterone in AR-V7 positive castrate-resistant prostate cancer (CRPC) patients, at the 2015 Genitourinary Cancers Symposium (ASCO GU) in Orlando, Florida.
Help employers find you! Check out all the jobs and post your resume.
